Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

Fouquet G, Marcq I, Debuysscher V, Bayry J, Rabbind Singh A, Bengrine A, Nguyen-Khac E, Naassila M, Bouhlal H.

Oncotarget. 2018 Feb 26;9(22):16248-16262. doi: 10.18632/oncotarget.24575. eCollection 2018 Mar 23. Review.

2.

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.

Taniwaki M, Yoshida M, Matsumoto Y, Shimura K, Kuroda J, Kaneko H.

Mediterr J Hematol Infect Dis. 2018 Feb 15;10(1):e2018014. doi: 10.4084/MJHID.2018.014. eCollection 2018. Review.

3.

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Cuesta-Mateos C, Alcaraz-Serna A, Somovilla-Crespo B, Muñoz-Calleja C.

Front Immunol. 2018 Jan 17;8:1936. doi: 10.3389/fimmu.2017.01936. eCollection 2017. Review.

4.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF.

Blood Adv. 2017 May 8;1(12):753-765. doi: 10.1182/bloodadvances.2017004382. eCollection 2017 May 9.

5.

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L, Bruno B.

Front Immunol. 2017 Nov 7;8:1444. doi: 10.3389/fimmu.2017.01444. eCollection 2017. Review.

6.

A compound chimeric antigen receptor strategy for targeting multiple myeloma.

Chen KH, Wada M, Pinz KG, Liu H, Shuai X, Chen X, Yan LE, Petrov JC, Salman H, Senzel L, Leung ELH, Jiang X, Ma Y.

Leukemia. 2018 Feb;32(2):402-412. doi: 10.1038/leu.2017.302. Epub 2017 Sep 27.

7.

Emerging drugs and combinations to treat multiple myeloma.

Larocca A, Mina R, Gay F, Bringhen S, Boccadoro M.

Oncotarget. 2017 Jul 15;8(36):60656-60672. doi: 10.18632/oncotarget.19269. eCollection 2017 Sep 1. Review.

8.

Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Barrow AD, Colonna M.

Semin Immunol. 2017 Jun;31:30-36. doi: 10.1016/j.smim.2017.09.001. Epub 2017 Sep 19. Review.

PMID:
28935344
9.

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Pazina T, James AM, MacFarlane AW 4th, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS.

Oncoimmunology. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853. eCollection 2017.

PMID:
28932638
10.

Chimeric antigen receptor T-cell therapies for multiple myeloma.

Mikkilineni L, Kochenderfer JN.

Blood. 2017 Dec 14;130(24):2594-2602. doi: 10.1182/blood-2017-06-793869. Epub 2017 Sep 19. Review.

PMID:
28928126
11.

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Malaer JD, Mathew PA.

Am J Cancer Res. 2017 Aug 1;7(8):1637-1641. eCollection 2017. Review.

12.

Novel Immunotherapies for Multiple Myeloma.

D'Agostino M, Boccadoro M, Smith EL.

Curr Hematol Malig Rep. 2017 Aug;12(4):344-357. doi: 10.1007/s11899-017-0397-7. Review.

PMID:
28819882
13.

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.

Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA.

Cancer Manag Res. 2017 Jul 12;9:307-314. doi: 10.2147/CMAR.S117477. eCollection 2017. Review.

14.

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D.

Oncoimmunology. 2017 Mar 28;6(5):e1308618. doi: 10.1080/2162402X.2017.1308618. eCollection 2017. Review.

15.

Elotuzumab as a novel anti-myeloma immunotherapy.

Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Review.

PMID:
28604269
16.

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.

Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, Han W.

Protein Cell. 2017 Dec;8(12):861-877. doi: 10.1007/s13238-017-0415-5. Epub 2017 May 9. Review. Erratum in: Protein Cell. 2017 Jun 23;:.

17.

Immunologic approaches for the treatment of multiple myeloma.

Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE.

Cancer Treat Rev. 2017 Apr;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. Epub 2017 Apr 6. Review.

18.

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Friend R, Bhutani M, Voorhees PM, Usmani SZ.

Drug Des Devel Ther. 2017 Mar 20;11:893-900. doi: 10.2147/DDDT.S98053. eCollection 2017. Review.

19.

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.

Suzuki K, Sunami K, Ohashi K, Iida S, Mori T, Handa H, Matsue K, Miyoshi M, Bleickardt E, Matsumoto M, Taniwaki M.

Blood Cancer J. 2017 Mar 10;7(3):e540. doi: 10.1038/bcj.2017.18. No abstract available.

20.

Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Holstein SA, McCarthy PL.

Drugs. 2017 Apr;77(5):505-520. doi: 10.1007/s40265-017-0689-1. Review.

Supplemental Content

Support Center